Get started
Stryker CorporationStryker CorporationStryker Corporation

Stryker Corporation

No trades
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonalsBondsETFs

Trade ideas

Looking for a discount stock with a good dividend yield?Looking for a discount stock with a good dividend yield? Then take a look at Stryker Corporation (SYK). With its cutting-edge technologies in robotics and minimally invasive surgery, Stryker Corporation is a leader in medical technology. With a strong presence in developed and emerging markets around the world, the company stands out for its innovation and commitment to improving medical care. The company has demonstrated remarkable financial stability, reporting impressive results in the fourth quarter of 2024 with EPS of $4.01 and revenue of $6.4 billion, exceeding analysts' forecasts. Consistent results are supported by a solid gross profit margin of 64 percent and return on invested capital of 13 percent, with an impressive 34-year history of dividend payments. Organic sales growth, at an annual rate of 10.2 percent, is a sign of the company's strong market presence and operational efficiency. Stryker recently acquired Inari Medica for $4.9 billion, marking its entry into the mechanical thrombectomy market. This strategic move demonstrates the company's commitment to optimize its portfolio and grow into new high-potential markets. At the same time, Stryker divested its spinal implant business as part of its repositioning strategy. In the long term, the management team expects organic sales growth of 9.75-10 percent by 2025. This growth will be supported by expansion initiatives in Europe, emerging markets, and the Asia-Pacific regions. I am confident in the potential of this stock and have decided to add it to my portfolio. By expanding into high-growth markets, such as mechanical thrombectomy through the acquisition of Inari Medical, Stryker should achieve significant revenue growth and exceed annual market growth rates of 20 percent. Focusing on international expansion, especially in emerging markets, could open up new revenue opportunities due to increased demand for advanced medical technologies and expanding healthcare infrastructure. Stryker's dedication to innovation, whether through internal development or strategic acquisitions, will likely be an important factor in maintaining its leading position in various segments of medical technology. This ongoing commitment to innovation will also strengthen its competitive position in the market. Through constant investment in research and development, the company is committed to integrating cutting-edge technologies to create innovative products. These products not only address unmet medical needs, but are also available at a price that is affordable to all. There are certain characteristics that define successful companies. For example, a steady increase in dividends for 15 consecutive years and a leading position in their industry. Here is a clear example of this concept. From a technical point of view, the trend is clearly defined and my target for this stock is $465. There is also good news on seasonality: last March the stock was up 20 percent. In summary, Stryker is an exceptional company with a long history of innovation in medical devices. Its diversified business has led to steady growth in revenues and profits for many decades. This has been made possible through significant investment in research and development as well as its acquisition strategy. The company still has many opportunities for growth, both in the United States, where health care spending is increasing due to an aging population, and internationally, where there is still a large untapped market.
NYSE:SYKLong
by Antonio_Ferlito
SYK pullback to $375MODs have suggested that I provide more detail about the picks I make. Sorry. I'm not as verbose as y'all, and I don't like things to be complicated. My trading plan is very simple. I buy or sell at top & bottom of parallel channels. I confirm when price hits Fibonacci levels. So... Here's why I'm picking this symbol to do the thing. Price at or above top of channels (period 100 52 39 & 26) Stochastic Momentum Index (SMI) at overbought level VBSM is spiked positive Price at 1.618 Fibonacci level In at $392 Target is $375 or channel bottom No stop loss. Will close manually.
NYSE:SYKShort
by chancethepug
Timing the market - what's wrong with buying at lower price ?Absolutely no UNLESS you have lots of spare cash or ignorant that you can get it at a lower price. Then again, who's right or wrong will depend on a later time when you look back. Look at Meta chart ( ) Of course, it could still comes down to close the gap before going up, the question is when . I also showed how long the gaps took to close in Amazon case. So, if you had done your due diligence, then you can buy in tranches ,like 10% to initiate a small position. Then, if it drops and close the gap, you can buy more at 15-20% depending on your capital. Spending too much time to TIME the market to me is a guessing game , sometimes you get lucky and other times you don't. Unless you like the hassle of monitoring the charts all day and get euphoric watching it , then go ahead else don't sweat the small stuff. Invest your time wisely !
NYSE:SYK
by dchua1969
Window Still OpenIn a first attempt to overcome the prevailing since October uptrend and to turn it around or achieve a major downward correction at least we have failed in April. Today some American players used the absence of the most other markets due to Labour Day to try it again. Nevertheless it became a dramatic fight against the bulls and the bears could not manage to close the January window. The bearish forces are obviously not yet strong enough to turn the trend around so that I expect the next attack of the bulls now. This week will show who wins.
NYSE:SYKLong
by motleifaul
SYK testing key resistanceStryker Corp. (SYK) presently trading above key resistance, able to absorb weekly selling pressures. A weekly settlement above this resistance zone would place (SYK) into a buy signal where gains of 20% would be expected over the following 3 - 5 months. Inversely, failing to close above this resistance level on a weekly basis, or closing back below this resistance level on a weekly basis, would lead to bearish momentum where losses of 20% would be expected over the same time horizon.
NYSE:SYK
by SpecialeAnalysis
SYK and IHI vs NVO's GLP1NYSE:SYK - The market is trying to price in the impact of NYSE:NVO and NYSE:LLY GLP1's on treatments associated with diabetes and obesity. This has led to a broad drawdown across medical devices, with IHI medical devices ETF dropping about 10% this week. Note the middle of this chart where I've compared IHI/NVO to SYK/NVO. SYK specializes in medical devices for neurotech, orthopedic, and spine which should have minimal overlap with health benefits of GLP1. Yesterdays open erased 2023 gains before reversing. It's unclear whether we can expect it to recover from here or test a deeper area of value between 220-240. As it recovers we should anticipate some selling pressure between 275-280.
NYSE:SYKLong
by Ben_1148x2